A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome
Phase of Trial: Phase II/III
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs Vatiquinone (Primary)
- Indications Leigh disease
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 28 Oct 2015 Status changed from recruiting to completed according to a Sumitomo Dainippon Pharma media release.
- 11 Mar 2014 The first patient has been enrolled, according to an Edison Pharmaceuticals media release.
- 11 Mar 2014 New trial record